Who was studied?
54 patients with metastatic solid tumors refractory to standard systemic therapy; response rates use the 54-patient ITT denominator, and safety analyses include 50 patients.
What does the publication report?
In the intention-to-treat population, ORR was 16.7% and DCR 46.3%. Median PFS was 4.0 months and median OS 10.5 months.
Reading the original figures
View full size ↗Read from left to right: repeated radiotherapy and immune-treatment cycles were followed by maintenance treatment and imaging assessments. This is the schedule of the 2022 study, rather than a universal schedule for every PRaG-derived approach.
© 2022 Kong et al. · Frontiers in Immunology, 2022 · Figure 1 · CC BY 4.0. Reproduced without alteration.
View full size ↗Each bar represents one response-evaluable patient. Bars below zero show shrinkage of nonirradiated target lesions; bars above zero show growth. Both responses and progression are visible. CR, PR, SD and PD denote the authors’ response categories; this uncontrolled study cannot establish superiority over another treatment.
© 2022 Kong et al. · Frontiers in Immunology, 2022 · Figure 3 · CC BY 4.0. Reproduced without alteration.
View full size ↗The left curve shows progression-free survival and the right overall survival in the study population. Time runs horizontally in months; the vertical axis shows the estimated proportion remaining without an event. These curves describe the cohort and are not predictions for an individual patient.
© 2022 Kong et al. · Frontiers in Immunology, 2022 · Figure 4 · CC BY 4.0. Reproduced without alteration.
Safety findings
Among 50 safety-assessed patients, five (10.0%) had grade 3 and one (2.0%) grade 4 treatment-related adverse events.
How should we interpret it?
Single-arm design, heterogeneous cancers and a small sample prevent a causal comparison with standard care.
Read the original source
This independently written summary was checked against the original full publication. It is an educational summary, not a full-paper translation or clinical recommendation.
PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study · DOI: 10.3389/fimmu.2022.952066 · PMID: 35874780
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.